Evolus, Inc. (LON:0K16)

Market Cap	700.77M
Revenue (ttm)	185.28M
Net Income (ttm)	-41.38M
Shares Out	n/a
EPS (ttm)	-0.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,342
Average Volume	3,893
Open	14.31
Previous Close	14.31
Day's Range	14.58 - 14.58
52-Week Range	7.12 - 15.38
Beta	n/a
RSI	65.90
Earnings Date	Mar 10, 2025

About Evolus

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 273
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K16

Financial Performance

In 2023, Evolus's revenue was $202.09 million, an increase of 35.98% compared to the previous year's $148.62 million. Losses were -$61.69 million, -17.10% less than in 2022.

Financial numbers in USD